Cystoid Macular Edema Associated with Omidenepag Isopropyl in Phakic Eyes after Laser Iridotomy: A Case Report-Reference-Cited by-同舟云学术

Cystoid Macular Edema Associated with Omidenepag Isopropyl in Phakic Eyes after Laser Iridotomy: A Case Report

Published:2021-10-25 Issue:5 Volume:88 Page:506-508
ISSN:1345-4676
Container-title:Journal of Nippon Medical School
language:en
Short-container-title:J Nippon Med Sch

Author:

Nakamoto Kenji¹,Shiratori Naka¹,Nishio Yusuke¹,Sugimoto Shio¹,Takano Yasuko¹,Yamazaki Masashi¹,Tobita Yutaro¹,Igarashi Tsutomu¹,Takahashi Hiroshi¹

Affiliation:

1. Department of Ophthalmology, Nippon Medical School

Publisher

Medical Association of Nippon Medical School

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/jnms/88/5/88_JNMS.2021_88-520/_pdf

Reference12 articles.

1. 1. The Japan Glaucoma Society. Ryokunaisho shinryo gaidorain dai 4 han [Guidelines for Glaucoma 4rd edition]. Nippon Ganka Gakkai Zashi [J Jpn Ophthalmol Soc]. 2018 Jan 10;122(1):3-53. Japanese.

2. 2. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology. 2014 Nov;121(11):2081-90.

3. 3. Heijl A. Glaucoma treatment: by the highest level of evidence. Lancet. 2015 Apr 4;385(9975):1264-6.

4. 4. Kim YY, Jung HR. Comparison of 2007-2012 Korean trends in laser peripheral iridotomy and cataract surgery rates. Jpn J Ophthalmol. 2014 Jan;58(1):40-6.

5. 5. Desideri LF, Cutolo CA, Barra F, et al. Omidenepag isopropyl for the treatment of glaucoma and ocular hypertension. Drugs Today (Barc). 2019 Jun;55(6):377-84.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cystoid macular edema associated with omidenepag isopropyl in a phakic eye with an implantable collamer lens: a case report;BMC Ophthalmology;2023-07-26

2. 緑内障に対する眼圧下降治療の現状と限界;Nihon Ika Daigaku Igakkai Zasshi;2023-04-20

3. Drugs used in ocular treatment;Side Effects of Drugs Annual;2022

4. Omidenepag-isopropyl;Reactions Weekly;2022-01